DeutschNewstral
Article
bizjournals.com on 2015-05-14 20:37
Former Dendreon CEO's new biotech Alpine Immune Sciences raises $1.3M
Related news
- Why ex-Dendreon CEO's new biotech startup could succeed where Dendreon failedbizjournals.com
- Seattle biotech Alpine Immune Sciences raises $91M for drug developmentbizjournals.com
Valeant wins Dendreon with $400M bidseattletimes.com- Dendreon lays off 77 including CEO W. Thomas Amickbizjournals.com
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024Star Tribune- Former Dendreon CEO, Amgen scientists team up on new immunotherapy startupbizjournals.com
- Biotech investor explains why Juno Therapeutics won't be like Dendreonbizjournals.com
Buyer of Dendreon lays off 77 Seattle employeesold.seattletimes.com- IVertex may have to pay more than $65 for Alpine Immune stock ($ALPN)invezz.com
- Valeant Pharmaceuticals approved to buy Dendreon for $495 millionbizjournals.com
- Dendreon sale for $495M approvedold.seattletimes.com
- Juno Therapeutics CEO gets $450,000 bonus, recruits former Amgen, Dendreon researchersbizjournals.com
- Valeant Pharmaceuticals to bid for Dendreon cancer drug in bankruptcy auctionbizjournals.com
- Dendreon extends deadline to see if anyone wants to buy the companybizjournals.com
- Bidder offers $296 million for Dendreon assetsseattletimes.com
- Dendreon says 2014 wasn't all horrible newsbizjournals.com
- Biotech company Dendreon extends metro Atlanta leasebizjournals.com
- Dendreon bidder bumps offer to $400 millionseattletimes.com
Not ImmuneThe New Yorker